Literature DB >> 5296382

Comparative value of sputum smear examination and culture examination in assessing the progress of tuberculous patients receiving chemotherapy.

S Devadatta, S Radhakrishna, W Fox, D A Mitchison, S Rajagopalan, S Sivasubramanian, H Stott.   

Abstract

Bacteriological response is generally considered the best criterion for assessing the efficacy of chemotherapy in patients with pulmonary tuberculosis. The bacteriological methods most commonly used are examination of sputum smears for tubercle bacilli, culture of bacilli from sputum specimens, and drug-sensitivity tests on positive cultures. Culture examination, though more sensitive than smear examination in detecting tubercle bacilli, is time-consuming and economically impracticable as a routine method in most developing countries. A study was therefore undertaken at the Tuberculosis Chemotherapy Centre, Madras, to determine the relative value of smear examination and culture examination in predicting the outcome of treatment and assessing the efficacy of chemotherapeutic regimens in 515 patients (all with bacteriologically confirmed disease and isoniazid-sensitive organisms on admission) receiving isoniazid, alone or with sodium PAS. The results showed that the value of smear examination of overnight sputum specimens at monthly intervals closely approached that of culture examination in assessing the progress of the patients, the percentages of correct predictions by smear and by culture being of the same order. Smear examination was slightly less effective than culture examination in detecting differences in the efficacies of regimens, but it has been estimated that this disadvantage can usually be compensated for by increasing the study population by about 20%.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5296382      PMCID: PMC2475995     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  REALISTIC CHEMOTHERAPEUTIC POLICIES FOR TUBERCULOSIS IN THE DEVELOPING COUNTRIES.

Authors:  W FOX
Journal:  Br Med J       Date:  1964-01-18

2.  Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate.

Authors:  S VELU; R H ANDREWS; J H ANGEL; S DEVADATTA; W FOX; P R GANGADHARAM; A S NARAYANA; C V RAMAKRISHNAN; J B SELKON; P R SOMASUNDARAM
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

3.  Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.

Authors:  S VELU; R H ANDREWS; S DEVADATTA; W FOX; S RADHAKRISHNA; C V RAMAKRISHNAN; J B SELKON; P R SOMASUNDARAM; T V SUBBAIAH
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

4.  The treatment of tuberculosis in the tropics.

Authors:  J R LAUCKNER
Journal:  J Trop Med Hyg       Date:  1959-01

5.  The chemotherapy of tuberculosis. With special reference to patients whose bacilli are resistant to the standard drugs.

Authors:  J CROFTON
Journal:  Br Med Bull       Date:  1960-01       Impact factor: 4.291

6.  A comparison of two methods of sputum collection in the diagnosis of pulmonary tuberculosis.

Authors:  R H ANDREWS; S RADHAKRISHNA
Journal:  Tubercle       Date:  1959-06

7.  Examination of smears for tubercle bacilli by fluorescence microscopy.

Authors:  E HOLST; D A MITCHISON; S RADHAKRISHNA
Journal:  Indian J Med Res       Date:  1959-09       Impact factor: 2.375

8.  A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS.

Authors:  J J Dawson; S Devadatta; W Fox; S Radhakrishna; C V Ramakrishnan; P R Somasundaram; H Stott; S P Tripathy; S Velu
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

9.  Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.

Authors:  S DEVADATTA; R H ANDREWS; J H ANGEL; A L BHATIA; W FOX; B JANARDHANAM; S RADHAKRISHNA; C V RAMAKRISHNAN; T V SUBBAIAH; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

10.  Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone.

Authors:  S DEVADATTA; A L BHATIA; R H ANDREWS; W FOX; D A MITCHISON; S RADHAKRISHNA; C V RAMAKRISHNAN; J B SELKON; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

  10 in total
  1 in total

1.  Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month.

Authors:  Aldar S Bourinbaiar; Uyanga Batbold; Yuri Efremenko; Munkhburam Sanjagdorj; Dmytro Butov; Narantsetseg Damdinpurev; Elena Grinishina; Otgonbayar Mijiddorj; Mikola Kovolev; Khaliunaa Baasanjav; Tetyana Butova; Natalia Prihoda; Ochirbat Batbold; Larisa Yurchenko; Ariungerel Tseveendorj; Olga Arzhanova; Erkhemtsetseg Chunt; Hanna Stepanenko; Nina Sokolenko; Natalia Makeeva; Marina Tarakanovskaya; Vika Borisova; Alan Reid; Valeryi Kalashnikov; Peter Nyasulu; Satria A Prabowo; Vichai Jirathitikal; Allen I Bain; Cynthia Stanford; John Stanford
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.